9 citations
,
January 2023 in “International Journal of Biological Sciences” CTHRC1 is essential for healing and preventing heart rupture after a heart attack.
2 citations
,
May 2011 in “Journal of Clinical Oncology” Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
9 citations
,
January 2015 in “Medical hypotheses” TCDD disrupts skin stem cells, causing skin issues like chloracne.
Dual TCR Treg cells are common in various mouse tissues and show diverse characteristics.
68 citations
,
August 2009 in “American Journal of Medical Genetics Part A” A new classification for trichothiodystrophy helps identify genetic causes and potential treatments.
August 2025 in “Skin Appendage Disorders” TCM is an effective and safe treatment for primary cicatricial alopecias.
52 citations
,
February 2012 in “PloS one” Lack of Ctip2 in skin cells delays wound healing and disrupts hair follicle stem cell markers in mice.
14 citations
,
January 2001 in “Current Treatment Options in Oncology” Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.
March 2026 in “Journal of the American Academy of Dermatology” The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.
November 1968 in “Journal of the American Pharmaceutical Association”
44 citations
,
November 2009 in “Archives of Dermatology” CYLD mutations cause a variety of skin tumors with symptoms starting around age 16, and treatments are currently limited.
1 citations
,
April 2010 in “Digital WPI” CLK1 is needed for skin cells to become epidermal cells but not sebocytes.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
3 citations
,
June 2018 in “Internal Medicine” Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
25 citations
,
October 2007 in “Developmental biology” Clim proteins are essential for maintaining healthy corneas and hair follicles.
March 2024 in “Research Square (Research Square)” Scalp cooling therapy helps preserve hair during chemotherapy for most patients.
1 citations
,
May 2019 in “Cytotherapy” The new ddPCR method reliably detects unwanted viruses in CAR-T cell products, ensuring their safety for patients.
January 2026 in “Dermatologic Therapy” Folliculotropic Mycosis Fungoides requires stage-based treatment, with early stages using skin therapies and advanced stages needing aggressive treatments.
14 citations
,
February 2020 in “Scientific reports” Telocytes in the scalp may help with skin regeneration and maintenance.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Clascoterone safely promotes hair growth similar to minoxidil.
September 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” Three genes linked to the development of trichilemmal cysts were found.
2 citations
,
May 2020 in “Journal of the American Academy of Dermatology” Hair shaft changes may be linked to CCCA, but their role is unclear.
March 2026 in “Tissue Engineering and Regenerative Medicine”
January 2022 in “Pharmaceutical Sciences Asia” The extract from Clitoria ternatea flowers helps human skin cells grow and promotes hair growth in mice.
Careful diagnosis and management of MCTD are crucial due to potential severe complications.
January 2007 in “Revista del Centro Dermatológico Pascua” A 2-year-old boy was diagnosed with a rare genetic condition causing fragile hair, intellectual issues, and short stature.
11 citations
,
January 2013 in “Indian Dermatology Online Journal” CCCA is a common, progressive hair loss condition that may not always be linked to hair care practices and requires a biopsy for diagnosis.
33 citations
,
August 2000 in “Experimental Cell Research” 33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.